The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence

Advances in Therapy

Volumn 36, Issue , 2019, Pages 5-12

  Davies, Alun H ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Cardiology; Chronic venous disease; Chronic venous insufficiency; Epidemiology; Treatment guidelines; Venoactive drug therapy; Venoactive drugs

Indexed keywords

DAFLON; DOBESILATE CALCIUM; PENTOXIFYLLINE; RUTOSIDE;

AWARENESS; CHRONIC DISEASE; CLINICAL CLASSIFICATION; COMPRESSION THERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE BURDEN; DISEASE EXACERBATION; HUMAN; LEG ULCER; NONHUMAN; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; REVIEW; ULCER; ULCER HEALING; VEIN DISEASE; LOWER LIMB; PATHOPHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULARIZATION; VEIN; VEIN INSUFFICIENCY;

CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; LOWER EXTREMITY; QUALITY OF LIFE; TREATMENT OUTCOME; VASCULAR DISEASES; VEINS; VENOUS INSUFFICIENCY;

EID: 85061631897     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-019-0881-7     Document Type: Review

References (45)

1. Lane TR, Sritharan K, Herbert JR, Franklin IJ, Davies AH. Management of chronic venous disease by primary care. Phlebology. 2013;28(6):299–304 (Epub 2012/09/20).
2. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maesenner M, Eklof B, et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254 (Epub 2018/06/07).
3. Marsden G, Perry M, Kelley K, Davies AH. Diagnosis and management of varicose veins in the legs: summary of NICE guidance. BMJ. 2013;347. 10.1136/bmj.f4279.
4. Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med. 1988;4(2):96–101 (Epub 1988/03/01).
5. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol. 2005;15(3):175–84 (Epub 2005/02/23).
6. Robertson L, Evans C, Fowkes FG. Epidemiology of chronic venous disease. Phlebology. 2008;23(3):103–11 (Epub 2008/05/10).
7. Robertson LA, Evans CJ, Lee AJ, Allan PL, Ruckley CV, Fowkes FG. Incidence and risk factors for venous reflux in the general population: Edinburgh Vein Study. Eur J Vasc Endovasc Surg. 2014;48(2):208–14 (Epub 2014/06/22).
8. Vuylsteke ME, Thomis S, Guillaume G, Modliszewski ML, Weides N, Staelens I. Epidemiological study on chronic venous disease in Belgium and Luxembourg: prevalence, risk factors, and symptomatology. Eur J Vasc Endovasc Surg. 2015;49(4):432–9 (Epub 2015/02/24).
9. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–15 (Epub 2012/04/03).
10. Barnes GD, Gafoor S, Wakefield T, Upchurch GR Jr, Henke P, Froehlich JB. National trends in venous disease. J Vasc Surg. 2010;51(6):1467–73 (Epub 2010/03/23).
11. Pappas PJ, Lakhanpal S, Nguyen KQ, Vanjara R. The Center for Vein Restoration Study on presenting symptoms, treatment modalities, and outcomes in Medicare-eligible patients with chronic venous disorders. J Vasc Surg Venous Lymphat Disord. 2018;6(1):13–24 (Epub 2017/12/19).
12. Moore HM, Lane TR, Thapar A, Franklin IJ, Davies AH. The European burden of primary varicose veins. Phlebology. 2013;28(Suppl 1):141–7 (Epub 2013/03/27).
13. Deitelzweig SB, Johnson BH, Lin J, Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011;86(2):217–20 (Epub 2011/01/26).
14. Onida S, Davies AH. Predicted burden of venous disease. Phlebology. 2016;31(1 Suppl):74–9 (Epub 2016/02/27).
15. Carradice D, Mazari FA, Samuel N, Allgar V, Hatfield J, Chetter IC. Modelling the effect of venous disease on quality of life. Br J Surg. 2011;98(8):1089–98 (Epub 2011/05/24).
16. Smith JJ, Garratt AM, Guest M, Greenhalgh RM, Davies AH. Evaluating and improving health-related quality of life in patients with varicose veins. J Vasc Surg. 1999;30(4):710–9 (Epub 1999/10/08).
17. Shepherd AC, Gohel MS, Lim CS, Davies AH. A study to compare disease-specific quality of life with clinical anatomical and hemodynamic assessments in patients with varicose veins. J Vasc Surg. 2011;53(2):374–82 (Epub 2010/12/07).
18. Carroll C, Hummel S, Leaviss J, Ren S, Stevens JW, Everson-Hock E, et al. Clinical effectiveness and cost-effectiveness of minimally invasive techniques to manage varicose veins: a systematic review and economic evaluation. Health Technol Assess. 2013;17(48):i–xvi, 1–141 (Epub 2013/11/02).
19. Brittenden J, Cotton SC, Elders A, Ramsay CR, Norrie J, Burr J, et al. A randomized trial comparing treatments for varicose veins. N Engl J Med. 2014;371(13):1218–27 (Epub 2014/09/25).
20. Kostas T, Ioannou CV, Touloupakis E, Daskalaki E, Giannoukas AD, Tsetis D, et al. Recurrent varicose veins after surgery: a new appraisal of a common and complex problem in vascular surgery. Eur J Vasc Endovasc Surg. 2004;27(3):275–82 (Epub 2004/02/05).
21. Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18–26 (Epub 2015/01/01).
22. Pannier F, Rabe E. The relevance of the natural history of varicose veins and refunded care. Phlebology. 2012;27(Suppl 1):23–6 (Epub 2012/02/15).
23. Pannier F, Rabe E. Progression in venous pathology. Phlebology. 2015;30(1 Suppl):95–7 (Epub 2015/03/03).
24. O’Donnell TF, Balk EM, Dermody M, Tangney E, Iafrati MD. Recurrence of varicose veins after endovenous ablation of the great saphenous vein in randomized trials. J Vasc Surg Venous Lymphat Disord. 2016;4(1):97–105 (Epub 2016/03/08).
25. Bush RG, Bush P, Flanagan J, Fritz R, Gueldner T, Koziarski J, et al. Factors associated with recurrence of varicose veins after thermal ablation: results of the recurrent veins after thermal ablation study. Sci World J. 2014;2014:505843 (Epub 2014/03/05).
26. Gohel MS, Davies AH. Pharmacological agents in the treatment of venous disease: an update of the available evidence. Curr Vasc Pharmacol. 2009;7(3):303–8 (Epub 2009/07/16).
27. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4:CD003229 (Epub 2016/04/07).
28. Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF). Phlebology. 2017;32(1_suppl):3–19 (Epub 2017/02/18).
29. Carpentier P, van Bellen B, Karetova D, Hanafiah H, Enriquez-Vega E, Kirienko A, et al. Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial. Int Angiol. 2017;36(5):402–9 (Epub 2017/02/17).
30. das Gracas CdSM, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694–702 (Epub 2018/03/29).
31. de Souza M, Cyrino FZ, Mayall MR, Virgini-Magalhaes CE, Sicuro FL, de Carvalho JJ, et al. Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon(R) 500 mg) on microvascular damage elicited by sclerotherapy. Phlebology. 2016;31(1):50–6 (Epub 2014/12/18).
32. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon(R)) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37(2):143–54 (Epub 2018/02/02).
33. Katsenis K. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency. Curr Vasc Pharmacol. 2005;3(1):1–9 (Epub 2005/01/12).
34. Tsukanov YT, Tsukanov AY. Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice. Phlebolymphology. 2017;24(3):144–51.
35. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S (Epub 2011/05/06).
36. Wittens C, Davies AH, Baekgaard N, Broholm R, Cavezzi A, Chastanet S, et al. Editor’s choice—management of chronic venous disease: clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678–737 (Epub 2015/04/30).
37. Marsden G, Perry M, Bradbury A, Hickey N, Kelley K, Trender H, et al. A cost-effectiveness analysis of surgery, endothermal ablation, ultrasound-guided foam sclerotherapy and compression stockings for symptomatic varicose veins. Eur J Vasc Endovasc Surg. 2015;50(6):794–801 (Epub 2015/10/05).
38. Shepherd AC, Ortega-Ortega M, Gohel MS, Epstein D, Brown LC, Davies AH. Cost-effectiveness of radiofrequency ablation versus laser for varicose veins. Int J Technol Assess Health Care. 2015;31(5):289–96 (Epub 2015/12/31).
39. Gohel MS, Epstein DM, Davies AH. Cost-effectiveness of traditional and endovenous treatments for varicose veins. Br J Surg. 2010;97(12):1815–23 (Epub 2010/10/06).
40. Tassie E, Scotland G, Brittenden J, Cotton SC, Elders A, Campbell MK, et al. Cost-effectiveness of ultrasound-guided foam sclerotherapy, endovenous laser ablation or surgery as treatment for primary varicose veins from the randomized CLASS trial. Br J Surg. 2014;101(12):1532–40 (Epub 2014/10/03).
41. Millenium Research Group—DRG. Varicose Vein Treatment Devices|US|2015| Market Analysis. Global Information, Inc.; 2015 [cited 2018]; Available from: https://www.giiresearch.com/report/mrg202059-us-markets-varicose-vein-treatment-devices-2011.html. Accessed 15 Dec 2018.
42. Laing W. Chronic venous diseases of the leg. London: Office of Health Economics; 1992.
43. Rabe E, Pannier F. Societal costs of chronic venous disease in CEAP C4, C5, C6 disease. Phlebology. 2010;25(Suppl 1):64–7 (Epub 2010/10/05).
44. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. J Med Econ. 2014;17(5):347–56 (Epub 2014/03/15).
45. Varatharajan L, Thapar A, Lane T, Munster AB, Davies AH. Pharmacological adjuncts for chronic venous ulcer healing: a systematic review. Phlebology. 2016;31(5):356–65 (Epub 2015/06/04).